Glenmark
A new way for a new world

July 16, 2018

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

Ref: Scrip Code: 532296

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai 400 051.

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Update on intimation made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Acquisition of 100% equity shareholding in Zorg Laboratories Private Limited (Zorg) by Glenmark Pharmaceuticals Limited (the Company)

Reference is made to the intimation made to the Stock exchanges on May 29, 2018 by the Company in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, about the approval of the Board for the proposal to acquire 100% stake in Zorg.

We now wish to inform you that our Company has completed the formalities for the acquisition of the equity stake and has acquired the 100% equity share holding of Zorg.

You are requested to take the same on record.

Thanking You.

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.

Harish Kuber
Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Ltd.
Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India
T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com